|
|
Vaccine Detail
|
Recombinant Fowlpox-Prostate Specific Antigen Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Fowlpox-Prostate Specific Antigen Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007160
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: KLK3
- KLK3
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for Prostate Cancer (NCT00005039). A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA). Administration of this agent may stimulate a cytotoxic T cell response against PSA-expressing tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells (NCI04) (NCIT_C2675; Arlen et al., 2007).
|
| Host Response |
|
|
| References |
Arlen et al., 2007: Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Steinberg SM, Jones E, Chen C, Marte J, Parnes H, Wright J, Dahut W, Schlom J, Gulley JL. Clinical safety of a viral vector based prostate cancer vaccine strategy. The Journal of urology. 2007; 178(4 Pt 1); 1515-1520. [PubMed: 17707059].
NCIT_C2675: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2675]
NCT00005039: [https://clinicaltrials.gov/show/NCT00005039/]
|
|
